Skip to main content
SpringerLink
Log in

Maraviroc

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▲ Maraviroc is a specific, slowly reversible, noncompetitive, small-molecule antagonist of the CCR5 chemokine receptor, which also serves as an HIV-1 coreceptor. By acting as an antagonist at the CCR5 coreceptor, maraviroc inhibits HIV-1 from entering host cells.

  • ▲ Clinical data for maraviroc are available from two large, well designed, ongoing phase IIb/III trials (MOTIVATE-1 and MOTIVATE-2) conducted in patients infected with R5-tropic HIV-1 who had previously received at least one agent from three of the four classes of antiretroviral drugs and/or were triple-class resistant.

  • ▲ According to 24-week interim results of the MOTIVATE-1 and -2 trials, a significantly greater reduction in viral load occurred in patients receiving maraviroc 150 or 300mg (depending on optimised background therapy [OBT]) twice daily plus OBT compared with placebo plus OBT. This significant difference was maintained at 48 weeks in MOTIVATE-1.

  • ▲ In the MOTIVATE-1 and -2 trials, a significantly greater proportion of patients receiving maraviroc plus OBT achieved an HIV-1 RNA level <400 and <50 copies/mL compared with those receiving placebo plus OBT. In addition, the CD4+ cell count was increased to a significantly greater extent with maraviroc plus OBT compared with placebo plus OBT.

  • ▲ The 48-week results of MOTIVATE-1 also report a significant difference in favour of maraviroc for all these endpoints.

  • ▲ In general, maraviroc at dosages of up to 300mg twice daily was well tolerated in treatment-experienced patients infected with R5-tropic HIV-1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Joint United Nations Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic [online]. Available from URL: http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp [Accessed 2007 Mar 23]

  2. Palani A, Tagat JR. Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. J Med Chem 2006; 49(10): 2851–7

    Article  PubMed  CAS  Google Scholar 

  3. Castagna A, Biswas P, Beretta A, et al. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 2005; 65(7): 879–904

    Article  PubMed  CAS  Google Scholar 

  4. Weber J, Piontkivska H, Quiñones-Mateu ME. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Reviews 2006; 8(2): 60–77

    PubMed  Google Scholar 

  5. Wood A, Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem 2005; 43: 239–71

    Article  PubMed  CAS  Google Scholar 

  6. Alcorn K, Carter M. Maraviroc shows potent effect in highly treatment-experienced [online]. Available from URL: http://www.aidsmap.com/en/news/8820C4DF-72D1-455A-A7ED-279152F673D7.asp [Accessed 2007 Mar 26]

  7. Pullen S, Sale H, Napier C, et al. Maraviroc is a slowly reversible antagonist at the human CCR5 in a CRE luciferase reporter gene assay [abstract no. 504, plus poster]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–9; Denver (CO)

  8. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 Nov; 49(11): 4721–32

    Article  PubMed  CAS  Google Scholar 

  9. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005 Nov; 11(11): 1170–2

    Article  PubMed  Google Scholar 

  10. Mosier DE, Picchio GR, Gulizia RJ, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73(5): 3544–50

    PubMed  CAS  Google Scholar 

  11. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagnoist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007 Mar; 81(5): 2359–71

    Article  PubMed  CAS  Google Scholar 

  12. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006 May; 80(10): 4909–20

    Article  PubMed  CAS  Google Scholar 

  13. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results from a phase 2b/3 study in the US and Canada [abstract no 104bLB, plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)

  14. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results [abstract no. 104aLB, plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)

  15. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase 3 studies MOTIVATE 1 and MOTIVATE 2 originates from a preexisting minority of CXCR4-using virus [abstract no. 56, plus poster and oral presentation]. XVI International HIV Drug Resistance Workshop; 2007 Jun 12–16; Barbados

  16. Pfizer Inc. Antiviral drugs advisory committee briefing document: maraviroc tablets NDA 22-128 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4283b1-00-index.htm [Accessed 2007 Apr 25]

  17. Russell D, Weissgerber G, Wooldridge C, et al. Investigation into the haemodynamic effects of oral maraviroc (UK-427,-857) in healthy volunteers [abstract no. H-874]. 10th European AIDS Conference; 2003 Sep 14–17; Chicago (IL)

  18. Ayoub A, Van der Ryst E, Turner K, et al. A review of the markers of immune function during the maraviroc phase I and IIa studies [abstract no. 509]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)

  19. Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857 — a new potential treatment for HIV. Drug Metab Dispos 2005 Apr; 33(4): 587–95

    Article  PubMed  CAS  Google Scholar 

  20. Pfizer Inc. Selzentry (maraviroc) tablets: highlights of the US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/022128lbl.pdf [Accessed 2007 Aug 8]

  21. Abel S, Van der Ryst E, Muirhead GJ, et al. Pharmacokinetics of single and multiple oral doses of UK-427,857 — a novel CCR5 antagonist in healthy volunteers [abstract no. 547]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston (MA)

  22. Russell D, Bakhtyari A, Jazrawi RP, et al. Multiple dose study to investigate the safety of UK-427,857 (100mg or 300mg) bid for 28 days in healthy males and females [abstract no. H-874, plus poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL)

  23. Rosario MC, Poland B, Sullivan J, et al. A pharmacokineticpharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 2006 Jun; 42(2): 183–91

    Article  PubMed  CAS  Google Scholar 

  24. FDA Maraviroc Review Team. FDA cover memorandum [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4283b1-00-index.htm [Accessed 2007 Apr 25]

  25. Abel S, Russell D, Ridgway C, et al. The effect of CCR5 antagonist UK-427,857, on the pharmacokinetics of CYP3A4 substrates in healthy volunteers [abstract no. 5.7]. 5th International Workshop on Clinical Pharmacology and HIV Therapy; 2004 Apr 1–3; Rome

  26. Abel S, Whitlock L, Ridgway C, et al. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427,857 in healthy young women [abstract no. A-1619]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL)

  27. Muirhead G, Russel D, Abel S, et al. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract no. P282]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  28. Muirhead G, Abel S, Russel D, et al. An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract no. P283]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  29. Muirhead G, Ridway C, Leahy D, et al. A study to investigate the combined coadministration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [abstract no. P284]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  30. Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [abstract no. 5.4]. 5th International Workshop on Clinical Pharmacology and HIV Therapy; 2004 Apr 1–3; Rome

  31. Abel S, Russell D, Ridgway C, et al. The effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [abstract no. 5.8]. 5th International Workshop on Clinical Pharmacology and HIV Therapy; 2004 Apr 1–3; Rome

  32. Abel S, Taylor-Worth R, Ridgway C, et al. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers [abstract no. LBPE4.3/15]. 10th European AIDS Conference; 2005 Nov 17–20; Dublin

  33. Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427,857 in HIV +ve subjects [abstract no. 663]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  34. Hyland R, Jones B, Muirhead G. In vitro assessment of the CYP-based drug-drug interaction potential of UK-427,857 [abstract no. 5.9]. 5th International Workshop on Clinical Pharmacology and HIV Therapy; 2004 Apr 1–3; Rome

  35. Mayer H, Van Der Ryst E, Saag M, et al. Safety and efficacy of Maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixedtropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract no THLB0215, plus oral presentation]. 16th International AIDS Conference — Programme Supplement 2006 Aug 13; Suppl.: 27-7. Plus oral presentation at the 16th International AIDS Conference; 2006 Aug 13; Toronto (ON)

  36. Lalezari J, Mayer H. Efficacy and safety of maraviroc in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract no H-718a]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)

  37. Proestel S. FDA analyses of maraviroc safety data [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/ 07/slides/2007-4283s1-02-02-FDA_Proestel.ppt [Accessed 2007 Jul 23]

  38. Pfizer’s Celsentri® approved in the European Union, providing a novel treatment option for treatment-experienced HIV patients [online]. Available from URL: http://mediaroom.pfizer.com [Accessed 2007 Sep 24]

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ∣ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Natalie J. Carter & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Natalie J. Carter & Gillian M. Keating

Authors
  1. Natalie J. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natalie J. Carter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carter, N.J., Keating, G.M. Maraviroc. Drugs 67, 2277–2288 (2007). https://doi.org/10.2165/00003495-200767150-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767150-00010

Keywords

Search

Navigation